ReviewDiabetes/metabolism research and reviews2025
Tubular Injury in Diabetic Kidney Disease: Early Diagnosis and Intervention Strategies.
Review in Diabetes/metabolism research and reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Impact of Omega Fatty Acids on DKD: A Multimodal Study Integrating Mendelian Randomization, Proteomic Mediation Analysis, and Meta-Analysis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Pooled it
- Advances in targeted treatment of ferroptosis in diabetic kidney disease with SGLT2 inhibitors.Diabetology & metabolic syndrome · 2026Review
- Zinc Potentiates the Renoprotective Effects of SGLT2 Inhibitors in Experimental Diabetes Mellitus in Rats.Life (Basel, Switzerland) · 2026Article
- Steam-Driven Structural Remodeling ofFoods (Basel, Switzerland) · 2026Article
- Article
- Molecular pathways and emerging therapeutic targets in the pathogenesis of diabetic kidney disease.Frontiers in physiology · 2026Review
- The role of gut microbiome disruption in the development of metabolic dysfunction-associated kidney disease.Acta biochimica Polonica · 2026Review
- Prognostic significance of interstitial fibrosis and tubular atrophy in biopsy-proven diabetic kidney disease: a single-center retrospective cohort study.Frontiers in endocrinology · 2026Article
- Urinary NGAL and NGAL/creatinine as tubular biomarkers in type 2 diabetes.Bioinformation · 2026Article
- Tubular Injury in Diabetic Kidney Disease: Early Diagnosis and Intervention Strategies.Diabetes/metabolism research and reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is the most severe complication of diabetes mellitus and has poor prognosis, often progressing to end-stage renal disease, causing substantial morbidity and mortality globally. While the pathogenesis of DKD has been extensively characterised, including glomerular hyperfiltration, podocyte injury, and tubulointerstitial fibrosis, recent findings underscore renal tubular injury as a pivotal contributor to DKD progression. High glucose levels and lipid accumulation result in tubular injury, followed by oxidative stress, endoplasmic reticulum stress, inflammation, activation of the renin-angiotensin-aldosterone system, programmed cell death, epithelial-mesenchymal transition, and intercellular crosstalk, all of which exacerbate tubular dysfunction in DKD. Notably, biomarkers of renal tubular injury, including kidney injury molecule-1, cystatin C, neutrophil gelatinase-associated lipocalin, liver fatty acid-binding protein, monocyte chemoattractant protein-1, N-acetyl-beta-glucosidase, and retinol-binding protein, along with other promising novel biomarkers, emerge earlier than microalbuminuria and serve as novel diagnostic indicators for early DKD detection. Therapeutically, we critically evaluate both established agents and emerging strategies, including hypoglycemic agents, anti-oxidative stress therapies, anti-inflammatory therapies, anti-cell death therapies, and stem cell therapy, showing promise for mitigating DKD-related tubular damage. This comprehensive review constructs a logical framework linking molecular mechanisms, novel biomarkers, and emerging therapeutic strategies for renal tubular injury in DKD. By bridging molecular mechanisms with actionable therapeutic strategies, this review highlights the pivotal role of tubulopathy in DKD pathogenesis and its implications for early diagnosis and intervention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.